294 results on '"Feldman, B. M."'
Search Results
2. Assessments of outcome in haemophilia – what is the added value of QoL tools?
3. A simple pediatric post-thrombotic syndrome classification algorithm for the general practitioner: OR328
4. Response to ‘limits of agreement between raters are required for use of HJHS 2.1 in clinical studies’
5. Systematic review with meta-analysis: magnetic resonance enterography signs for the detection of inflammation and intestinal damage in Crohnʼs disease
6. Validation of the Actiheart activity monitor for measurement of activity energy expenditure in children and adolescents with chronic disease
7. Chinese Hemophilia Joint Health Score 2.1 reliability study
8. Entrapment of herbal extracts into biodegradable microcapsules
9. Polyelectrolyte microcapsules as the systems for delivery of biologically active substances
10. Erratum: European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides - The SHARE initiative (Rheumatology (2019)58 (656-671) DOI: 10.1093/rheumatology/key322)
11. A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial N-of-1 trials design
12. Haemophilia prophylaxis: how can we justify the costs?
13. Quality of life in the assessment of hemophilia: S-TU-03.1-3
14. Outcome assessment and limitations
15. Implementing musculoskeletal outcome assessments in clinical practice
16. Effect of intracranial bleeds on the neurocognitive, academic, behavioural and adaptive functioning of boys with haemophilia
17. Joint health and functional ability in children with haemophilia who receive intensive replacement therapy
18. Age at first joint bleed and bleeding severity in boys with severe hemophilia A: Canadian Hemophilia Primary Prophylaxis Study
19. Session S2.3: Hemophilia joint health score (HJHS) reliability study in China: 22FP15
20. Risk factors for development of uveitis differ between girls and boys with juvenile idiopathic arthritis
21. 2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria—methodological aspects
22. Long term (10 year) results from the canadian hemophilia primary prophylaxis study: AS-WE-003
23. Acute renal failure in paediatric systemic lupus erythematosus: treatment and outcome
24. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A
25. Musculoskeletal measurement tools from the International Prophylaxis Study Group (IPSG)
26. Quality of randomized clinical trials in juvenile idiopathic arthritis
27. Assessment of an infectious disease history preceding juvenile dermatomyositis symptom onset
28. Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group
29. The economics of haemophilia prophylaxis: governmental and insurer perspectives. PROCEEDINGS OF THE SECOND INTERNATIONAL PROPHYLAXIS STUDY GROUP (IPSG) SYMPOSIUM
30. The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy
31. Epidemiology of Juvenile Idiopathic Arthritis in a Multiethnic Cohort: Ethnicity as a Risk Factor
32. Prevalence, Risk Factors, and Outcome of Uveitis in Juvenile Idiopathic Arthritis: A Long-Term Followup Study
33. Definitions for haemophilia prophylaxis and its outcomes: The Canadian Consensus Study
34. RISK OF NEW-ONSET UVEITIS IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS TREATED WITH ANTI-TNFα AGENTS
35. Hemophilia joint health score reliability study
36. Tumour necrosis factor α inhibitors in the treatment of childhood uveitis
37. An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM)
38. Recent developments in clinimetric instruments
39. Pilot study of fitness training and exercise testing in polyarticular childhood arthritis
40. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study
41. Hemophilia joint health score instructional video and manual: 18 FP 532
42. Predictors of Disease Course and Remission in Systemic Juvenile Idiopathic Arthritis: Significance of Early Clinical and Laboratory Features
43. Developing a disease activity tool for systemic-onset juvenile idiopathic arthritis by international consensus using the Delphi approach
44. The Effectiveness of Treating Juvenile Dermatomyositis With Methotrexate and Aggressively Tapered Corticosteroids
45. What does ‘active disease’ mean? patient and parent perceptions of disease activity in the systemic arthritis form of juvenile idiopathic arthritis (SO-JIA)
46. Cost of severe haemophilia in Toronto
47. Proceedings of the International Haemophilia Prophylaxis Study Group Meeting, November 2003, Montreal, PQ, Canada
48. Physical therapy and imaging outcome measures in a haemophilia population treated with factor prophylaxis: current status and future directions
49. Cost–utility analysis in evaluating prophylaxis in haemophilia
50. Health-related quality-of-life treatments for severe haemophilia: utility measurements using the Standard Gamble technique
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.